Non Small-Cell Lung Cancer Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Others), by Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy), by Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2025 - 2034

Non Small-Cell Lung Cancer Market Size and Trends

The global non-small cell lung cancer market size is calculated at USD 20.09 billion in 2024, grow to USD 22.00 billion in 2025, and is projected to reach around USD 49.78 billion by 2034, growing at a CAGR of 9.5% from 2025 to 2034. The market is growing due to the rising prevalence of lung cancer and the increased use of targeted therapies like EGFR and ALK inhibitors. Additionally, advancements in immunotherapies and early diagnostic techniques are boosting treatment demand.

Key Takeaways

• North America dominated the non-small cell lung cancer market in 2024.
• Asia-Pacific is expected to grow at the highest CAGR in the market during the forecast period.
• By type, the adenocarcinoma segment dominated the market.
• By type, the squamous cell carcinoma segment is expected to grow at the fastest CAGR in the market during the studied years.
• By treatment, the targeted therapy segment held the largest market share.
• By treatment, the immunotherapy segment is expected to grow at the fastest CAGR in the market during the studied years.
• By distribution channel, the hospital pharmacy segment led the market in 2024.
• By distribution channel, the drug store and retail pharmacy segment is expected to grow at the fastest CAGR in the market
• during the studied years.

How is the Non-small Cell Lung Cancer Market Evolving?

Non-small cell lung cancer is the most common type of cancer accounting for about 80-85% of all lung cancer cases. It is a group of cancers that arises from the epithelial cells of the lung and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC generally grows and spreads more slowly than small-cell lung cancer and treatment options depend on the specific subtype and stage of the disease. The non-small cell lung cancer market evolving with a strong focus on targeted therapies, immunotherapy advancement, and personalized treatment approaches. The rise in biomarker testing and companies' diagnostics is enabling more precise drug development. Breakthroughs like ANKTIVA and other checkpoint inhibitor combinations are improving survival in resistance cases. Additionally increasing clinical trials, regulatory approvals, and adoption of liquid biopsies are transforming the treatment landscape and enhancing patient outcomes across different stages of NSCLC.

• For Instance, In April 2024, ImmunityBio shared promising outcomes from its QUILT 3.055 trial, showing that ANKTIVA (nogapendekin alfa inbakicept-pmln), when used with checkpoint inhibitors, significantly improved survival rates in patients with second- and third-line non-small cell lung cancer (NSCLC) who had not responded to earlier treatments.

What are the Key Trends in the Non-small Cell Lung Cancer Market in 2025?

• In October 2024, Novocure received FDA approval for Optune Lua, a wearable device designed to treat adults with metastatic non-small cell lung cancer (NSCLC) that has advanced following platinum-based chemotherapy. The device uses Tumor Treating Fields (TTFields), a unique approach that applies alternating electric fields to interfere with cancer cell division, ultimately causing cell death. This marks a new, non-invasive option for patients with limited treatment choices.
  
  
• In May 2024, Pfizer shared extended follow-up findings from the Phase 3 CROWN trial comparing LORBRENA to XALKORI in treating ALK-positive advanced non-small cell lung cancer (NSCLC). With a median follow-up of five years, LORBRENA demonstrated a significant benefit, showing an 81% reduction in disease progression, highlighting its long-term effectiveness in managing this specific NSCLC subtype.

How Can AI Affect the Non-small Cell Lung Cancer Market?

AI is transforming the market by enhancing early detection through advanced imaging analysis, improving diagnostic accuracy with AI-driven pathology, and identifying genetic mutations for targeted therapies. It accelerates drug discovery, streamlines clinical trials with predictive analytics, and personalizes treatment plans using patient data. AI also supports real-time monitoring and decision-making, leading to more effective and timely interventions, ultimately improving survival rates and reducing healthcare costs in NSCLC management.

Report Scope of Non Small-Cell Lung Cancer Market

Market Dynamics

Driver

The Growing Adoption of Targeted Therapies and Immunotherapies
The growing adoption of targeted therapies and immunotherapies is a major driver in the non-small cell lung cancer market because these treatments offer greater precision and effectiveness by focusing on specific genetic mutations or immune checkpoints. Unlike traditional chemotherapy, they improve survival rates and reduce side effects. With increasing biomarker testing and personalized medicine approaches, more patients are eligible for these advanced therapies, leading to better treatment outcomes and fueling market growth.

• For Instance, In June 2025, the FDA approved Ibtrozi (taletrectinib), a next-generation oral ROS1 inhibitor, for ROS1 positive NSCLC—offering a precision-based treatment tailored to a specific genetic mutation.

Restraint

Late Diagnosis

Late detection of non-small cell lung cancer hinders effective disease management, as more cases are only identified after symptoms appear and the cancer has progressed. This delay reduces the potential benefits of early interventions like localized surgery or targeted therapies. As a result, patients often face limited therapeutic options and poorer clinical outcomes. Moreover, late-stage diagnosis complicates clinical trial eligibility and adds to the economic burden on both patients and healthcare systems.

Opportunity

The Expansion of Liquid Biopsy and Non-invasive Diagnostics

Liquid biopsy and other non-invasive diagnostic tools offer a promising future in the non-small cell lung cancer market by simplifying the detection of genetic alterations and disease progression without the need for surgical procedures. These methods enable clinicians to assess tumor dynamics more frequently, helping to identify treatment resistance early and adapt therapies accordingly. Their growing adoption supports timely intervention, improves patient comfort, and accelerates the shift towards precision oncology, making cancer care more responsive and personalized.

• For Instance, In November 2024, the FDA approved FoundationOne® Liquid CDx as a companion diagnostic for tepotinib in NSCLC patients with MET exon 14 skipping mutations. This marked a major step in using liquid biopsy to guide targeted treatment non-invasively.

Segmental Insights

How Does the Adenocarcinoma Segment Dominate the Non-small Cell Lung Cancer Market in 2024?

Adenocarcinoma leads the market due to rising incidence globally and the strong response of advanced molecular-targeted therapies. Its clear genetic profile enables the use of personalized treatments, making it more manageable compared to other subtypes. The availability of approved drugs for mutations commonly found in adenocarcinoma, along with increased screening and biomarker testing, further boosts its dominance in clinical practice and market share.

The squamous carcinoma segment is projected to grow rapidly in the non-small cell lung cancer market due to a surge in research focused on hard-to-treat histologies and limited existing targeted therapies. As new treatment options, particularly immune-oncology drugs, show effectiveness in the subtype, demand is increasing. Furthermore, the growing emphasis on subtype-specific clinical trials and improved diagnostics differentiation is opening new avenues for therapeutic development, contributing to the market acceleration.

How Does the Squamous Cell Carcinoma Segment Dominate the Non-small Cell Lung Cancer Market?

Targeted therapies dominated the market as they offer precision-based treatment tailored to individual tumor profiles, resulting in improved response rates. Their growing preference stems from the success of mutation-specific drugs that slow disease progression and enhance quality of life. The increasing approvals of targeted agents across various genetic subtypes have further strengthened their clinical value, making the market most widely adopted in modern NSCLC care.

• For Instance, In October 2023, the FDA approved Pfizer’s combination therapy of encorafenib and binimetinib (BRAFTOVI + MEKTOVI) for treating metastatic NSCLC with the BRAFV600E mutation. This targeted treatment is approved for use in both newly diagnosed and previously treated patients, offering a new option specifically tailored to this genetic subtype.

Why Did the Hospital Pharmacy Segment Dominate the Non-small Cell Lung Cancer Market in 2024?

The hospital pharmacy segment dominated the market in 2024 as most advanced therapies require on-site administration and close clinical oversight. Hospitals are better equipped with diagnostic tools, multidisciplinary teams, and the infrastructure needed for managing complex cancer treatments. Moreover, papatientsith severe or late-stage NSCLC are often treated in hospital settings, where access to newly approved drugs and participation in the clinical protocol is more streamlined, driving higher drug distribution through hospital-based pharmacies.

The drug store and retail pharmacy segment is projected to grow rapidly in the non-small cell lung cancer market as more patients shift towards home-based care and prefer easily accessible medication sources. The increasing approval of oral cancer drugs that don’t require hospital visits is fueling demand through retail outlets. Additionally, retail pharmacies are expanding and enhancing medication adherence factors that contribute to their rising role in cancer treatment distribution.

Regional Insights

How is North America Contributing to the Expansion of the Non-small Cell Lung Cancer Market?

North America dominated the market due to its advanced healthcare infrastructure, early adoption of innovative therapies, and strong presence of key pharmaceutical companies. High awareness, widespread availability of diagnostic tools, and favorable reimbursement policies support early detection and treatment. Additionally, a high incidence of lung cancer and increased investment in precision medicine and clinical research contribute to the region’s leadership in driving both market growth and therapeutic advancements in NSCLC care.

• For Instance, In August 2024, U.S., AstraZeneca’s Imfinzi (durvalumab) received approval for treating adults with resectable early-stage (IIA–IIIB) non-small cell lung cancer (NSCLC) lacking EGFR mutations or ALK rearrangements. The treatment involves using Imfinzi alongside neoadjuvant chemotherapy before surgery, followed by Imfinzi alone as adjuvant therapy after surgery. This combined approach aims to improve outcomes in early-stage NSCLC patients eligible for surgery.

How is the Asia Pacific Accelerating the Non-small Cell Lung Cancer Market?

Asia-Pacific is expected to grow at the highest CAGR in the market due to its large patient population, rising prevalence of smoking-related lung cancers, and improving healthcare infrastructure. Increasing government initiatives for cancer awareness, expanding access to advanced diagnostics and therapies, and growing investments by pharmaceutical companies are further driving market expansion. Additionally, the adoption of precision medicine and the rise in clinical trials across countries like China, India, and Japan support this rapid growth.

• For Instance, In July 2024, AstraZeneca India Private Limited (AZIPL) announced an investment of ₹250 crore (around USD 30 million) to expand its Global Technology and Innovation Centre (GITC) across various locations in India. This expansion will create around 1,300 new roles aimed at boosting operational efficiency, fostering innovation, and supporting AstraZeneca’s global functions through its Global Capability Centre (GCC).

Some of The Prominent Players in The Non Small-Cell Lung Cancer Market Include:

• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GSK plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.

Recent Development in the Non-small Cell Lung Cancer Market

• In July 2024, AstraZeneca India Private Limited (AZIPL) revealed plans to invest ₹250 crore (approximately USD 30 million) to grow its Global Technology and Innovation Centre (GITC) in multiple Indian cities. This initiative is set to generate around 1,300 jobs, with a focus on enhancing global operations, driving technological innovation, and improving overall efficiency through its Global Capability Centre (GCC).
  
  
• In April 2025, China’s National Medical Products Administration (NMPA) approved Akeso Inc.’s Ivonescimab, a novel bispecific antibody that targets both PD-1 and VEGF. The drug is approved as a first-line monotherapy for treating advanced non-small cell lung cancer (NSCLC) in patients who are PD-L1-positive (tumor proportion score ≥1%) and do not have EGFR or ALK mutations. This marks a significant advancement in immunotherapy for specific NSCLC patient groups.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Non Small-Cell Lung Cancer Market.

By Type

• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Others

By Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By Distribution Channel

• Hospital Pharmacy
• Drug Store and Retail Pharmacy
• Online Pharmacy

By Regional

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)